SavedAdd your journal

Journals / Van Sağlık Bilimleri Dergisi / 2021 / Cilt: 14 - Sayı: 3

No Association Between IRS2 Gly1057Asp Polymorphism and Esophageal Cancer

IRS2 Gly1057Asp Polimorfizmi ile Özofagus Kanseri Arasında İlişki Yoktur

İsmail GÜLAÇAR
Zehra KAYA
Necat ALMALI
Can ATEŞ
Gözde YEŞİL SAYIN
Gökhan GÖRGİŞEN
Pages
298–303
Publication Date
2021-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: There is no significant correlation between the IRS2 Gly1057Asp variant and the risk of esophageal cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The aim of this study was to figure out the relationship between IRS2 Gly1057Asp variant and susceptibility to esophageal cancer.
📊
Key Findings & Data:Material and Methods: A case-control study was conducted to select 70 esophageal cancer patients and 100 healthy control samples.
💡
Conclusion & Impact:Conclusion: There is no significant correlation between the IRS2 Gly1057Asp variant and the risk of esophageal cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:IRS2 Gly1057Asp · rs1805097 · Özofagus Kanseri

Abstract

Introduction: The aim of this study was to figure out the relationship between IRS2 Gly1057Asp variant and susceptibility to esophageal cancer. Material and Methods: A case-control study was conducted to select 70 esophageal cancer patients and 100 healthy control samples. Genomic DNA was extracted from peripheral whole blood samples and real time polymerase chain reaction (RT-PCR) based SNP genotyping was performed using predesigned Taqman assay. Results: There was no significant difference in the frequency distribution of genotypes between patients and control group. Conclusion: There is no significant correlation between the IRS2 Gly1057Asp variant and the risk of esophageal cancer.

Özet

Amaç: Bu çalışmanın amacı IRS2 Gly1057Asp varyantı ile özofagus kanseri yatkınlığı arasındaki ilişkiyi ortaya çıkarmaktır. Materyal ve Metod: Çalışma 70 özofagus kanseri ve 100 sağlıklı kontrol örneğini içeren vaka-kontrol çalışmasıdır. Genomik DNA, periferal kandan izole edilmiş olup, gerçek zamanlı polimeraz zincir reaksiyonu (RT-PCR) temelli SNP genotipleme için ticari olarak dizayn edilmiş Taqman assay kullanılmıştır. Bulgular: Genotip dağılımında hasta ve kontrol örnekler arasında anlamlı bir farklılık saptanmamıştır. Sonuç: IRS2 Gly1057Asp varyantı ile özofagus kanser gelişim riski arasında anlamlı bir ilişki belirlenememiştir.

🔖

Cite This Article

GÜLAÇAR, İ., KAYA, Z., ALMALI, N., ATEŞ, C., SAYIN, G. Y., GÖRGİŞEN, G. (2021). No Association Between IRS2 Gly1057Asp Polymorphism and Esophageal Cancer. Van Sağlık Bilimleri Dergisi, Cilt: 14 - Sayı: 3, 298–303. https://ajindex.com/articles/821434

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Alaouna M, Hull R, Penny C, Dlamini Z. Esophageal cancer genetics in South Africa. Clin Exp Gastroenterol. 2019; 12: 157–77.
  2. Boissan M, Beurel E, Wendum D et al. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol. 2005; 167: 869–877.
  3. Cayan F, Dilek S, G Ramazan, Ayaz L. Association of insulin receptor substrate-2 gene polymorphism with ovarian cancer. Balkan Med J. 2011; 28:14-7.
  4. Cayan F, Tok E, Aras-Ates N et al. Insulin receptor substrate 2 gene polymorphism: is it associated with endometrial cancer? Gynecol Endocrinol. 2010; 26: 378-82.
  5. Chan BT, Lee AV. Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 2008; 13: 415–422. D’Alfonso R, Marini MA, Frittitta L et al. Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 317-22.
  6. Day E, Poulogiannis G, McCaughan F et al. IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol. 2013; 94: 203–11.
  7. Dearth RK, Cui X, Kim HJ et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Molecular and Cellular Biology. 2006; 26: 9302-14.
  8. Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS- 2 in breast cancer metastasis. Cell Cycle. 2007; 6: 631-637.
  9. Gorgisen G, Gulacar IM, Ozes ON. The role of insulin receptor substrate (IRS) proteins in oncogenic transformation. Cell Mol Biol (Noisy-le-grand). 2017; 63(1): 1-5.
  10. Gorgisen G, Hapil FZ, Yilmaz O et al. Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer. Genet Mol Bio. 2019; 42: 15-25.
  11. Hu Y, Zhou M, Zhang K et al. Lack of association between insulin receptor substrate 2 rs1805097 polymorphism and the risk of colorectal and breast cancer: A meta-analysis. Plos One. 2014; 9: e86911. Lautier C, El Mkadem SA, Renard E et al. Complex haplotypes of IRS2 gene are associated with severe obesity and reveal heterogeneity in the effect of Gly1057Asp mutation. Hum Genet. 2003; 113: 34-43.
  12. Lin DC, Wang MR, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology. 2018; 154(2): 374-89.
  13. Lin MW, Huang MF, Wu MH. Association of Gly972Arg variant of insulin receptor subtrate-1 and Gly1057Asp variant of insulin receptor